List of drugs undergoing clinical trials in MPN | Download Scientific Diagram
Efficacy and safety of itacitinib versus placebo in combination with corticosteroids for initial treatment of acute graft-versus-host disease (GRAVITAS-301): a randomised, multicentre, double-blind, phase 3 trial - The Lancet Haematology
Exploring the safety, effect on the tumor microenvironment, and efficacy of itacitinib in combination with epacadostat or parsaclisib in advanced solid tumors: a phase I study | Journal for ImmunoTherapy of Cancer
Ongoing clinical trials of PD-1/PD-L1 immunotherapeutics in breast cancer | Download Table
Itacitinib prevents xenogeneic GVHD in humanized mice | Bone Marrow Transplantation
The Lancet Haematology on Twitter: "Zeiser also discussed GRAVITAS-301: addition of itacitinib, a JAK1 inhibitor, did not improve response compared with standard first line therapy for acute #GVHD. Corticosteroids remain the standard
Itacitinib | C26H23F4N9O - PubChem
Frontiers | New Approaches for the Treatment of Chronic Graft-Versus-Host Disease: Current Status and Future Directions | Immunology
Predicting Complete Response to Itacitinib and Corticosteroids in Acute Graft Versus Host Disease - Biology of Blood and Marrow Transplantation
![PDF] A phase 1 trial of itacitinib, a selective JAK1 inhibitor, in patients with acute graft-versus-host disease. | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/265b8d3517575964e518b92944c9558171cdf15d/6-Table1-1.png "PDF] A phase 1 trial of itacitinib, a selective JAK1 inhibitor, in patients with acute graft-versus-host disease. | Semantic Scholar")
PDF] A phase 1 trial of itacitinib, a selective JAK1 inhibitor, in patients with acute graft-versus-host disease. | Semantic Scholar
A Phase 1/2 Study of the Oral Janus Kinase 1 Inhibitors INCB052793 and Itacitinib Alone or in Combination With Standard Therapies for Advanced Hematologic Malignancies - Clinical Lymphoma, Myeloma and Leukemia
VisualAbstract: Addition of itacitinib to corticosteroids did not show clinical benefit over placebo in initial treatment of acute graft-versus-host disease | 2 Minute Medicine
JCI - Insights from integrating clinical and preclinical studies advance understanding of graft-versus-host disease
Cancers | Free Full-Text | Untwining Anti-Tumor and Immunosuppressive Effects of JAK Inhibitors—A Strategy for Hematological Malignancies? | HTML
Impact of itacitinib on xGVHD Survival (a), GVHD scoring (b) and weight... | Download Scientific Diagram
A phase 1 trial of itacitinib, a selective JAK1 inhibitor, in patients with acute graft-versus-host disease - ScienceDirect
![PDF] A phase 1 trial of itacitinib, a selective JAK1 inhibitor, in patients with acute graft-versus-host disease. | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/265b8d3517575964e518b92944c9558171cdf15d/7-Table1-1.png "PDF] A phase 1 trial of itacitinib, a selective JAK1 inhibitor, in patients with acute graft-versus-host disease. | Semantic Scholar")
PDF] A phase 1 trial of itacitinib, a selective JAK1 inhibitor, in patients with acute graft-versus-host disease. | Semantic Scholar
Completed and ongoing clinical trials assessing STAT3 pathway... | Download Scientific Diagram
Incyte Announces Results of Phase 3 Study of Itacitinib in Patients with Treatment-Naïve Acute Graft-Versus-Host Disease | Business Wire
Preclinical characterization of itacitinib (INCB039110), a novel selective inhibitor of JAK1, for the treatment of inflammatory diseases - ScienceDirect
Itacitinib adipate | C32H33F4N9O5 - PubChem
Ruxolitinib for the treatment of patients with steroid-refractory GVHD: an introduction to the REACH trials | Immunotherapy
Incyte sinks as itacitinib fails pivotal test in acute GVHD | Fierce Biotech
